Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4549081 | 0.81 | NOTUM (0.34) | CYP19A1ALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL20243770 | 0.80 | CYP19A1 (0.40) | CYP19A1ALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL30669699 | 0.80 | CYP19A1 (0.40) | CYP19A1ALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL28879999 | 0.79 | CYP19A1 (0.42) | CYP19A1ALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL2162474 | 0.79 | GABRA1 (0.42) | CYP19A1ALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL23599602 | 0.79 | CYP1A1 (0.30) | — | |
| SCHEMBL2372208 | 0.79 | TSHR (0.45) | CYP19A1ALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL2724407 | 0.79 | CYP19A1 (0.48) | CYP19A1ALDH1A1SMN1; SMN2MAPTCA1 | |
| SCHEMBL25620334 | 0.78 | CYP19A1 (0.41) | CYP19A1ALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL7461135 | 0.77 | TDP1 (0.38) | ALDH1A1SMN1; SMN2TSHRCA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936144-B | JAK inhibitors | 廖细斌 | 2023-12-22 | — | — | CN | claimed |
| EP-3143055-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | Bridgestone Corporation (JP) | 2017-03-22 | — | — | EP | claimed |
| WO-2015175280-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | WO | claimed |
| WO-2025085560-A1 | LYSINE ACETYLTRANSFERASE INHIBITORS | Kronos Bio, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-111936144-B | JAK inhibitors | 廖细斌 | 2023-12-22 | — | — | CN | disclosed |
| CN-114213410-B | Synthesis method of aromatic ring [ a ] carbazole compound and aromatic ring [ g ] pyridine indole compound | 湖南师范大学 | 2023-03-14 | — | — | CN | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114213410-A | Synthesis method of aromatic ring [ a ] carbazole compound and aromatic ring [ g ] pyridine indole compound | 湖南师范大学 | 2022-03-22 | — | — | CN | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| EP-1940856-A1 | NOVEL UROKINASE INHIBITORS | Universiteit Antwerpen (BE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045496-A1 | NOVEL UROKINASE INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2007-04-26 | — | — | WO | disclosed |
| US-6956046-B2 | 4-hydroxypiperidine derivatives having analgesic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-18 | — | — | US | disclosed |
| US-20040176410-A1 | 4-hydroxpiperdine derivative with analgetic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1391452-A1 | 4-HYDROXPIPERIDINE DERIVATIVE WITH ANALGETIC ACTIVITY | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1346994-A1 | CHOLESTEROL BIOSYNTHESIS INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT TRICYCLIC SPIRO COMPOUNDS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-4876266-A | DOPAMINE-B-HYDROXYLASE INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-10-24 | — | — | US | disclosed |
| EP-0329900-A1 | Substituted 1-aralkyl imidazoline-2-thiols | SMITHKLINE BEECHAM CORPORATION (US) | 1989-08-30 | — | — | EP | disclosed |
| WO-1989006126-A1 | 1-ARALKYL-2-MERCAPTOIMIDAZOLINES AS DOPAMINE-beta-HYDROXYLASE INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176410-A1 | 4-hydroxpiperdine derivative with analgetic activity | HNMT, HDAC1, HDAC3 | CYP19A1 1180/4885ALDH1A1 416/4885SMN1; SMN2 485/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | CYP19A1 2954/4885ALDH1A1 2649/4885SMN1; SMN2 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.